On October 29, 2021 Novo Nordisk reported that the full-year sales and operating profit outlook at constant exchange rates (CER) has been raised (Press release, Novo Nordisk, OCT 29, 2021, View Source [SID1234592189]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the third quarter of 2021, Novo Nordisk’s sales increased by 15% and operating profit increased by 19%, both at CER. The operating profit increase was positively impacted by the amortisation of the priority review voucher for Wegovy in the third quarter of 2020.

Following the financial results for the first nine months of 2021, the outlook for 2021 is updated. The updated outlook is reflecting higher than expected Ozempic market share gains, GLP-1 market growth and obesity care sales, mainly in the US.

Novo Nordisk’s full disclosure of the financial results for the first nine months of 2021 will be published on 3 November 2021.

The above expectations are based on assumptions including those described on pages 16 and 17 of the Financial report for the period 1 January 2021 to 30 June 2021 (Company Announcement No 48 / 2021).